- Business Wire•6 hours agoOmeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Corporation today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy from the company's Phase 2 clinical trial of OMS721 in TMAs, with clinically meaningful improvement in measures of red blood cell destruction, specifically lactate dehydrogenase and haptoglobin levels .
- Accesswire•8 hours ago
LONDON, UK / ACCESSWIRE / October 20, 2016 / Active Wall St. blog coverage looks at the headline from Omeros Corp. (NASDAQ: OMER ) as the company announced positive results from a Phase 2 clinical trial ...
- Business Wire•yesterdayOmeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse
Omeros Corporation today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor -gamma agonist in patients with cocaine use disorder .
Omeros Corporation (OMER)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||7.99 x 2200|
|Ask||8.00 x 700|
|Day's Range||7.61 - 8.27|
|52wk Range||7.20 - 16.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.21|
|Avg Vol (3m)||427,809|
|Dividend & Yield||N/A (N/A)|